Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study:

Aim:More than half of patients with breast, lung, or prostate cancer who have bone metastases have evidence of skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody that bi...